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INTRODUCTION
Neuroblastoma, the most common extra-cranial solid
tumor in children, originates as a primary tumor of the
sympathetic nervous system but metastasizes often to bone
and bone marrow, resulting in a poor prognosis. Approxi-
mately 15% of patients who present with metastatic disease
at diagnosis are refractory to induction chemotherapy while
40%will eventually relapse after having a complete response
(CR) or partial response (PR) [1].
Intravenous administration of radiolabeled metaiodoben-
zylguanidine (mIBG), a norepinephrine analog that specifi-
cally targets malignant cells of the sympathetic nervous
system, is an effective therapy for patients with refractory
disease, with response rates of 30–40% [2–8]. Many of the
patients who undergo therapy with 131I-mIBG or other
treatments for relapsed neuroblastoma have sites of disease
only apparent onmIBG scans or in bonemarrow biopsies and
cannot be evaluated by standard response criteria for solid
tumors, such as the RECIST criteria [9]. Therefore, a
standardized scoring system to predict the clinical response
and progression-free survival (PFS) with 131I-mIBG treat-
ment is needed to help quantitate therapeutic efficacy of
agents used in treatment of refractory neuroblastoma.
In recent analyses of high-risk, metastatic neuroblastoma,
semi-quantitative scoring systems that divide the body into
anatomical sections were developed to assign numeric scores
to patients’ diagnostic 123I and 131I-mIBG scans [10–14].
Assessing extent of disease before, during, and after
induction chemotherapy, three studies have shown a
correlation between semi-quantitative scores either at
diagnosis or during induction with response at the end of
induction chemotherapy [10,12,13] while another showed
good concordance among scan readers but poor correlation
with response [14].
Although some of these studies showed a significant
correlation between the change in semi-quantitative score
Background. The purpose of this study was to determine the
accuracy of two semi-quantitative scoring systems to assess response
to 131I-metaiodobenzylguanidine (mIBG) therapy in recurrent
neuroblastoma. Procedures. Diagnostic mIBG scan pairs (n¼57)
were collected for patients who underwent 131I-mIBG therapy for
relapsed neuroblastoma. Two scoring systems were designated:
Method 1, which divided the body into nine segments to view
osteomedullary lesions with an additional tenth segment to assess
soft tissue involvement; and Method 2, which divided the body into
seven segments without a corresponding compartment for soft tissue
involvement. Four nuclear medicine physicians independently
assigned extension and intensity scores utilizing both methods, and
separately recorded their impression of whether the post-therapy
scan had improved, not changed, or worsened. Inter- and intra-
observer concordance and correlation with overall response and
progression-free survival (PFS) were performed. Results. Method 1
produced the highest inter-observer concordance and was used to
calculate the relative extension scores (post-therapy score divided by
pre-therapy score), which correlated significantly with overall
response. Patients who achieved complete response (CR) or partial
response (PR) (n¼21) had lower relative extension scores, compared
to those without response (P<0.001). The readers’ overall impres-
sion associated highly (P< 0.001) with the relative extension scores
though results were less quantitative. Concordance was higher if
initial scores were >5. Relative extension score did not predict PFS.
Conclusion. Semi-quantitative scoring of mIBG scans provides a
more reliable method of assessing response in patients with relapsed
neuroblastoma than qualitative impression. The reproducibility and
high inter-observer concordance makes mIBG score an important
component of overall response criteria in patients with recurrent
neuroblastoma.Pediatr Blood Cancer 2006;47:865–874.
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and patient response to induction chemotherapy, each used
slightly different methods to assign scores. In addition, these
scoring systems have only been tested in newly diagnosed
neuroblastoma patients. No investigation has been performed
to correlate results from these scoring systems to response
among neuroblastoma patients with refractory or relapsed
disease later in the treatment course. In such patients,
changes in score might be expected to be smaller, and the
number of lesions at initiation of treatment would frequently
be less than at the time of original diagnosis for stage 4
neuroblastoma.
Based on an analysis of patients who have been treated
with 131I-mIBG in a Phase II study for refractory disease, the
present study sought to determine whether or not methods
from two semi-quantitative scoring systems correlated with
response to therapy based on International Neuroblastoma
Response Criteria (INRC) [15] and PFS in a relapse
population. This study also evaluated inter- and intra-
observer concordance among the four independent readers




This study included 49 patients with relapsed or refractory
neuroblastoma who were treated at the University of
California, San Francisco (n¼ 36), the Children’s Hospital
of Philadelphia (n¼ 7), and the University of Michigan
(n¼ 6) between February 20, 1998 and December 11, 2003
on the clinical trial, 131I-Metaiodobenzyguanidine Therapy
for Neuroblastoma: a Phase II study [7]. Patient character-
istics are shown in Table I. Patients were treated with 444–
666 MBq/kg of 131I-mIBG for one (n¼ 42), two (n¼ 6), or
three (n¼ 1) courses. Although some patients had only a few
lesions, they all had relapsed metastatic disease, with high
likelihood of other sub-clinical lesions, and therefore were
candidates for the targeted radionuclide rather than local
radiaotherapy. Patients were evaluated as described below
for response approximately 2weeks prior to each therapy and
8 weeks after each therapy. Appropriate informed consent
was obtained for all patients with approval at each center by
the institutional human research review board and radiation
safety committee.
mIBG Scoring Method
mIBG scans were performed using a standard protocol, as
described in [16]. Four nuclear medicine physicians (B.T.,
B.F., M.C., B.S.) assigned scores to 57 pre- and post-therapy
mIBG diagnostic scan pairs based upon two semi-quantita-
tive scoring systems (Table II) [10,12]. Extension scores
were assigned to each segment to quantify the extent of
mIBG-positive lesions within a given segment. Intensity
scores were assigned to each segment to quantify the degree
of mIBG uptake within the lesions of a given segment. The
present study differentiated between the two scoring systems
as Method 1 and Method 2. For Method 1, the patient’s
skeleton was divided into nine segments to view osteome-
dullary lesions with an additional tenth segment to assess soft
tissue involvement (Fig. 1A) [10,13]. For Method 2, the
skeleton was divided into seven segments to view osteome-
dullary lesions without a corresponding compartment to
assess soft tissue involvement (Fig. 1B) [12,14].
Absolute pre-therapy extension, post-therapy extension,
pre-therapy intensity, and post-therapy intensity scores were
calculated for Methods 1 and 2 by summing the segmental
scores assigned by the readers. In each region, the lesions
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE I. Patient Characteristics






Amplified 12/34 tested (35.29%)
Time from diagnosis to
metaiodobenzylguanidine
(mIBG) treatment (years)
Median [range] 2.6 [0.6–11.8]
Age at mIBG treatment (years)




Sites of disease at time of
mIBG treatment
Bone/bone marrow, soft tissue 26
Bone/bone marrow only 13
Soft tissue only 10
TABLE II. mIBG Scan Characteristics
Characteristic Number of mIBG scans
Number of scans revieweda
Paired pre- and post-therapy scans 57








Time interval between MIBG therapy
and post-therapy scan (weeks)
Median 7
Range [3–12]
Scans with SPECT Viewsb 8
Scans with lateral views of skull 55
aIn four cases, the post-therapy scan from the first MIBG treatment
served as the pre-therapy scan for the second treatment.
bScores from the SPECT views were not used in the analysis.
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were scored as follows for extension of metastases. The
extension score for Method 1 was graded as: 0, no sites per
segment; 1, one site per segment; 2, more than one site per
segment; and 3, diffuse involvement (>50% of the segment).
An example of the scoring by the four readers is shown in
Figure 2A,B. The extension score for Method 2 was graded
as: 0, no sites per segment; 1, one site per segment; 2, more
than one site per segment. The intensity score for both
methods was graded as: 0, for no uptake; 1, for doubtful
uptake; 2, for obvious uptake; and 3, for strong uptake. Thus,
the maximum extension and intensity score for Method
1 would be 30 and 30, and the maximum scores for Method
2 would be 14 and 21, respectively. The relative extension
and intensity scores were calculated by dividing the absolute
post-therapy score by the absolute pre-therapy score.
The four readers scored the scan pairs independently from
identical hard copies of the scans as digital copies were not
available in many of the patients. Readers were blinded to
both the clinical history of the patient’s disease and to the
patient’s overall response to 131I-mIBG therapy. To maintain
consistency in the scoring process, general guidelines were
established before the readers began scoring scans: (1)
information as to whether or not a patient had a prior
adrenalectomy or nephrectomy due to tumor involvement
was provided, so that the readers could differentiate between
physiologic uptake in an adrenal gland or kidney and active
disease on the diagnostic mIBG scan; (2) the pre-treatment
scan was scored before the post-treatment scan usingMethod
1 followed by Method 2; (3) physiologic uptake of mIBG in
the liver was used as a point of reference to determine
whether or not areas of abnormal uptake were of high or low
intensity; and (4) when multiple sites of disease with varying
intensities were present within a given segment, the intensity
score for that segment was based upon the lesion with the
greatest intensity. Finally, the readers also rated a patient’s
overall qualitative response to 131I-mIBG based on their
analysis of the diagnostic mIBG scan pair. Disregarding
numeric score, the readers recorded their impression of
whether the post-therapy scan had improved, not changed, or
worsened in comparison to the pre-therapy scan.
To measure intra-observer consistency, three patients’
scan pairs were chosen to be scored on a second occasion in a
blinded fashion by the four readers. These three patients’scan
pairs were selected based upon extent of disease to determine
whether or not variations arose within a reader’s results in
scoring widespread versus localized disease.
Response Evaluation
Response to 131I-mIBG therapy based upon INRC was
rated as CR, very good partial response (VGPR), PR, mixed
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 1. A: Method 1, The patient’s skeleton is divided into nine segments to view osteomedullary lesions [11] with an additional tenth segment to
assess soft tissue osteomedullary lesions [11] with an additional tenth segment to assess soft tissue. B: Method 2, The patient’s skeleton is divided
into seven segments to view osteomedullary lesions [10].
mIBG Scoring in Relapsed Neuroblastoma 867
response (MR), no response (NR), or progressive disease
(PD). Response was determined (prior to the current scoring
study) by radiological review of post-therapy mIBG, CTand
MRI scans, morphologic analyses of bone marrow, and
vanillylmandelic acid (VMA) and homovanillic acid
(HVA) levels in urine [15]. Pre-therapy evaluation was
done after a patient finished any prior therapeutic regimen
and no earlier than 6 weeks before 131I-mIBG treatment.
Post-therapy response evaluation was required at 6–8 weeks
post-mIBG treatment and before a patient moved onto a new
therapeutic regiment.
One patient’s scores were excluded from the INRC
response and overall impression analyses after determining
that the pre-therapy mIBG scans were inadequate for
response assessment. This patient still had scans included
for the inter-observer concordance and was included in the
overall PFS analysis.
Statistical Analysis
Toquantify the concordance in scoring among readers, the
analysis used the generalized concordance correlation
coefficient (CCC) [17,18]. The 95% confidence interval for
CCC and the P-value for comparing concordance were
calculated based on bootstrap bias-corrected confidence
limits [19]. To assess the reader agreement on overall
response impression, the analysis used the k-type statistics of
O’Connell and Dobson [20]. We assigned impression scales
1, 0, and 1 to categories improved, not changed, and
worsened, respectively, and used two choices of disagree-
ment function (o1 ando0 inO’Connell andDobson: with and
without partial agreement).
Given the definitions of the relative scores in the mIBG
Scoring Method section, a value of zero for the pre-therapy
absolute score would result in an ill-defined relative score.
When a reader assigned a pre-therapy absolute extension and
intensity scores of 0 because he did not see any evidence of
disease on the pre-therapymIBG scan, this reader’s scorewas
excluded from the analysis of relative scores. This was
particularly a problem for Method 2, which excluded score
assignment for soft tissue lesions.
Correlation of scores with response was examined using
logistic regression and generalized additivemodels [21]. The
Wilcoxon rank sum test was used to compare continuous
scores. Proportions of response were compared by the Fisher
exact test and trend in proportions was assessed by the
Cochran–Armitage test. The accuracy of using the relative
score or impression as a prognostic test for response was
summarized in terms of false positive fractions, positive
predictive values as well as positive and negative diagnostic
likelihood ratios (DLR), and the accuracy of two tests was
compared by their relative DLR [22].
PFS was defined as the amount of time in months between
131I-mIBG therapy and disease progression or death. For
patientswho receivedmultiple therapies, the date of their first
therapy was used to determine the time between therapy and
disease progression. Survival and PFS curves were estimated
by the Kaplan–Meier method and compared by the log-rank
test [23]. In the PFS analysis, the time to disease progression
was censored at the time a patient went on new therapy or at
the time of the last follow-up visit. The proportion of patients
changed to new therapy was estimated by its cumulative
incidence rate with disease progression being a competing
risk [24].
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Fig. 2. A: Pre-therapy 123I-metaiodobenzylguanidine (MIBG) scan
and extension score by Method 1 by four readers. B: Post-therapy 123I-
MIBG scan and extension score by Method 1 by four readers.
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RESULTS
Inter- and Intra-Observer Score Concordance
Table III summarizes the pre- and post-therapy scores for
all patients and gives the inter-observer concordance. In all
cases, the inter-observer concordance for absolute scoreswas
greater than or equal to 0.88. Method 1 absolute extension
scores produced the highest inter-observer concordance
among the four raters. The absolute extension score
concordance was marginally higher than the absolute
intensity score concordance for both methods. The relative
score concordance was lower for both methods in compar-
ison to the absolute score concordance.
To determine whether relative extension score concor-
dance differed based upon extent of disease pre-therapy, the
patient population was stratified into two groups based upon
pre-therapy Method 1 absolute extension scores. Figure 3
shows the distribution of median (among four readers) pre-
therapy extension scores. There were 25 scans with the
median score 3, 4 scans with the score >3 but 5, and 28
scanswith the score>5. Thus, the stratification offive sites of
disease pre-therapy was chosen as the cut-point for the
analysis. The relative extension and intensity concordance
for Method 1 scoring was significantly higher for the groups
with more extensive disease, either scores >3 (P< 0.02) or
>5 (P< 0.01) (Table IV).
To evaluate the association of relative scores with the
outcomes (INRC response and PFS), the median of the four
readers’ Method 1 extension scores was used to compute the
relative extension score for each scan. These scores were
utilized because they produced very high inter-observer
concordance, accounted for soft tissue lesions, and themedian
statistic is more robust than the mean. We also compared the
median relative extension scores with the median relative
intensity scores (correlation coefficient¼ 0.88) and found no
significant difference. In terms of high (>0.5) versus low
(0.5) relative scores, the relative intensity and extension
scores gave the same classifications except for one case
(extension¼ 0.42, intensity¼ 0.71).
For the intra-observer analysis of the four readers, three
pairs of pre- and post-therapy scans were read on two
separate blinded occasions. The scans had median pre-
therapy scores of 2, 14, and 19 in order to have a range of low
(5) and high (>5) scores. Consistent with the results of the
inter-observer concordance analysis, there was better agree-
ment in scoring scans with high scores in comparison to low
scores. Only 2 of these 12 pairs of relative scores resulted in a
change in category between low (0.5) and high (>0.5)
relative scores. Similarly, for the response by qualitative
impression, 10/12 pairs were concordant and only 2 pairs of
impression scores were discrepant for response.
When assessing soft tissue lesions, certain inconsistencies
arose in scoring for both methods. For Method 1, 13 patients
received pre-therapy scores from multiple readers for the
10th compartment without any documented soft tissue
involvement by other imaging modalities. In addition,
10 patients, who only had evidence of soft tissue disease
pre-therapy, should have received soft tissue scores for
the 10th compartment from all readers, but in 7 of the
10 cases, at least one reader gave a soft tissue score of 0. For
Method 2, this same group of 10 patients should have
received pre-therapy scores of 0 for all compartments due to
lack of bone and bone marrow disease but 8 had scores
mistakenly assigned as skeletal disease by at least one of the
four readers.
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TABLE III. Scores and Inter-Observer Concordance on 57 Paired
mIBG Scans




Pre-therapy Method 1 4.50 [0–30] 0.92 (0.86, 0.96)
Post-therapy Method 1 3.00 [0–30] 0.92 (0.82, 0.96)
Pre-therapy Method 2 2.50 [0–14] 0.91 (0.84, 0.94)
Post-therapy Method 2 1.50 [0–14] 0.89 (0.80, 0.94)
Absolute intensity scores
Pre-therapy Method 1 6.50 [0–30] 0.91 (0.86, 0.94)
Post-therapy Method 1 4.00 [0–30] 0.88 (0.80, 0.93)
Pre-therapy Method 2 4.50 [0–21] 0.90 (0.85, 0.93)
Post-therapy Method 2 2.50 [0–21] 0.89 (0.82, 0.92)
Relative extension scoresa
Method 1 0.90 [0.00–3.50] 0.47 (0.35, 0.61)
Method 2 0.85 [0.00–3.00] 0.48 (0.31, 0.65)
Relative intensity scoresa
Method 1 0.79 [0.00–3.33] 0.58 (0.43, 0.73)
Method 2 0.69 [0.00–5.00] 0.51 (0.39, 0.69)
aFor Method 1, six pre-therapy scans received absolute scores of 0: two
scans by two readers and four scans by one reader. ForMethod 2, which
did not include scores for soft tissue lesions, 18 pre-therapy scans
received absolute scores of 0: 2 scans by all four readers, 2 scans by three
readers, 7 scans by two readers, and 7 scans by one reader.
Fig. 3. Distribution of median pre-therapy extension scores. [Color
figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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Correlation of Score With Response
There were 56 scan pairs associated with valid INRC
response data, including 4 with CR, 17 with PR, 27 with
NR (including 2 with MR), and 8 with PD. Figure 4A shows
the relative extension score by Method 1 grouped by
response. As shown by the outliers, seven therapies, that
were scored as having a response with a relative score of
0.5, did not achieve CR or PR by other modalities, such as
CT scan or bone marrow analysis (Table V). Conversely, six
therapies failed to achieve response by relative score but still
achieved response by INRC. Among these six therapies, five
patients had low absolute pre-therapy extension scores (5)
and also intermediate relative scores, and one therapy,
with an absolute pre-therapy extension score of 7 and a
median relative score of 1.04, resulted in NR by mIBG scan
but PR by CT. However, for this study, we used the
median score, where the individual response by INRC was
previously derived from an impression by a single nuclear
medicine reader.
The Method 1 relative extension score correlated with
response to 131I-mIBG therapy based on INRC, such that
patients who achieved CR (n¼ 4) or PR (n¼ 17) had
significantly lower relative extension scores (P< 0.001),
with median score of 0.31 (CI 0.11, 0.51), compared to NR/
PD (n¼ 35), with median of 0.98 (CI 0.90, 1.06) (Fig. 4A).
Based on a linear logistic model, patients with low relative
extension scores were significantly more likely to have a CR
or PR to 131I-mIBG therapy (P< 0.001) such that the odds of
a CR or PR became about sixfold when relative extension
scores drop by 0.5. Proportions of response (CR or PR) by
INRC showed a significant decreasing trend (P< 0.001)
among patients with low (0.5), intermediate (>0.5 but1),
and high (>1) relative extension scores. Of those who had a
low relative score, 68% (15/22) had a response by INRC
while only 20% (5/25) of those with an intermediate relative
score and 11% (1/9) of those with a high relative score still
achieved response. Compared to those with an intermediate
score, patients with a low scorewere estimated to be 3.4 times
(CI 1.5, 8.9) likely to achieve a response. The likelihood of
response for patients with a high score was 0.56-fold (CI
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE IV. Concordance for Method 1 mIBG Score After Stratification by Extent of Disease (mIBG
Score of 3 or 5) Pre-Therapy
Extension concordance Intensity concordance
Pre Post Relative P Pre Post Relative P
Low (3) 0.23 0.35 0.33 <0.02 0.38 0.55 0.46 <0.02
High (>3) 0.88 0.91 0.66 0.86 0.88 0.78
Low (5) 0.27 0.34 0.28 <0.01 0.42 0.54 0.43 <0.01
High (>5) 0.87 0.91 0.80 0.84 0.89 0.86
Fig. 4. A: Relationship between median relative score and tumor
response to mIBG therapy by International Neuroblastoma Response
Criteria (INRC). Xmarks themean; the barmarks themedian; the lower
and upper border mark the first (Q1) and the third (Q3) quartiles,
respectively, complete response (CR)/partial response (PR) (n¼ 21), no
response (NR)/progressive disease (PD) (n¼ 35); P< 0.001. The five
outliers with high relative score (iÝ1) in the CR/very good partial
response (VGPR)/PR group had very low initial scores and poor
agreement. B: Impression and relative extension score. Improved
(n¼ 29), not changed (n¼ 20), worsened (n¼ 7).
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0.02, 4.02) compared to those with an intermediate score,
although the difference was not significant.
We also examined the correlation of response with relative
score according to pre-therapy disease score using the
stratification of 5 (low) and >5 (high). Proportions of
response did not differ significantly (P> 0.9) between the two
pre-therapy strata for patients with a low (0.5) relative score,
and likewise (P> 0.4) for patients with a high (>1) relative
score. However, for those with an intermediate relative score,
33% (5/15) achieved response (1 CR and 4 PR) in the low
stratum compared to 0% (0/10) in the high stratum (P¼ 0.06).
Inter-Observer Overall Response
Impression Agreement
Impression of each scanwas summarized as improved, not
changed, or worsened for the INRC response and PFS
analyses. Of the 57 scans, 23 (40%) scan pairs had a ‘perfect’
agreement (all four raters agreed); 20 (35%) had a ‘majority’
agreement (the same impression by three readers with the
impression by the other reader differing by one category);
8 scans had a ‘closely-split’ agreement (two readers agreed
with each other, and the two readers differed by one
category); the other 6 scan pairs had mixed impressions.
Allowing for partial agreement, agreement is perfect (¼1.0)
for 40%, excellent for 49%, and good (between 0.6 and 0.8)
for 11% of the scans.
Using the impression scales (described above), of the
scans in perfect or majority agreement, 24, 14, and 4 scans
(excluding 1 inevaluable for response) were classified as
improved, not changed, and worsened, respectively. The
readers’ overall impression of response associated well
(P< 0.001 with or without excluding the scans in mixed
agreement) with the relative extension scores although these
results were less quantitative (Fig. 4B).
However, the use of the impression scorewas less accurate
than the semi-quantitative scoring system for prediction of a
good (positive) response. The relative accuracy of the relative
score compared to the impression score was evaluated by
comparing their DLRs to predict response. For the relative
score, the positive DLR was 3.57 compared to 2.36 for the
impression score, and the negative DLR was 0.36 compared
to 0.29. That is, the odds of response increased by 3.57-fold
with knowledge of a low (0.5) relative score compared to
only 2.36-fold by an improved impression. The relative
positive DLR was 1.52, implying that a positive result on
relative score is more indicative of response than impression.
However, the relative negativeDLRwas 1.23, implying that a
negative result on relative score is less convincing for non-
response than a negative impression result. The lower
accuracy of a negative result on relative score can be
improved by taking the pre-therapy score into account for
patientswith a relative score between 0.5 and 1.0 as discussed
in the previous section.
Score and PFS
Survival and PFS for all patients are shown in Figure 5A.
The PFS curve is truncated as patients were censored when
they went on to new therapy. PFS according to pre-therapy
stratum of score5 or>5 showed a trend for improved PFS
with a lower pre-therapy score (P¼ 0.20) (Fig. 5B). The
relative extension score of 0.5 or >0.5 did not appear to
affect PFS (Fig. 5C) and became even less significant when
considering both disease progression and switching to new
therapy as endpoint (P¼ 0.73). The reversal of the expected
order of the curves in Figure 4C is explained by the fact that
patients with higher relative scores, and therefore poorer
response to the mIBG therapy, were about twice as likely to
change to new therapy earlier, and therefore, be censored in
the PFS analysis when compared to those with a lower
relative score. In fact, by 4 months, 57% of patients with a
high relative score>0.5 had changed to new therapy, and by
6 months post-mIBG therapy, 70% had changed, whereas
28% and 39% of patients with a low relative score had
changed to new therapy by 4 and 6 months, respectively.
Ultimately, overall response by INRC to mIBG therapy had
no effect on PFS in this group of 49 refractory patients (data
not shown). This findingwas consistent with the lack of effect
of relative score on PFS.
DISCUSSION
Several studies have shown that incorporation of mIBG
scan results into analysis of response is critical both for
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE V. Patients With Relative Scores 0.5 but No Response (NR) by International Neuroblastoma Response Criteria (INRC)
Patient #
Median relative
extension score Response by INRC Comments
49 0.50 Progressive disease (PD) Previously negative bone marrow became positive for disease post-therapy
48 (Third therapy) 0.50 PD New nodule in breast positive for neuroblastoma by fine needle aspirate
102 0.33 NR Bone marrow remained positive post-therapy
159 0.35 NR Bone marrow remained positive post-therapy
84 0.41 PD Increase in tumor size on CT
158 0.34 PD Previously negative bone marrow became positive for disease post-therapy
58 0.43 PD Previously negative bone marrow became positive for disease post-therapy
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determining response and survival [11,25–28]. An objective
and consistent method for interpretation of these scans is
therefore critical for comparison of clinical outcomes. A
prior study [10], using Method 1 to score patients at
diagnosis, had a median pre-therapy extension score of 18,
compared to the current study, with a median score of 4.5.
The results of the current study show that semi-quantitative
scoring of mIBG scans is reliable in relapsed neuroblastoma
despite the lower median score, with excellent inter- and
intra-observer concordance, similar to results for newly
diagnosed patients [10,13,14]. We have shown further that
the calculation used in the relative score for response
continues to be reliable though more error is introduced in
patients with fewer than three to five lesions prior to therapy.
Extension and intensity score concordances were very
similar. Overall, the data showed no advantage in using both
scores to assess response, and there was only one instance
where the relative intensity score fell into a different category
for response than the relative extension score.
Method 1 relative extension scores can be used accurately
for semi-quantitative analysis of response by mIBG scan in
refractory patients and correlate significantlywithwhether or
not a patient had an overall response (CR, VGPR, or PR) or
no response (NR, MR, or PD) by INRC to therapy. Based
upon the results displayed in Figure 4A, the present study
shows that a relative extension score of0.5 indicates that a
patient likely had a response tomIBG therapy by INRC, and a
relative extension score of>0.5 indicates that a patient likely
had NR.
Relative extension scores had the highest concordance
among readers for patients with more than three to five sites
of disease. For patients with fewer sites of disease, because
the post-therapy score is divided by the pre-therapy score to
calculate the relative score, a single digit difference assigned
by the four raters in either of these scores will have a
significant effect on this ratio. The data suggest that any
decrease in absolute score is indicative of response in patients
with scores below three to five at the commencement of
therapy, but that the semi-quantitative scoring system is most
useful in those with pre-treatment score 3.
Method 2 (without assigning soft tissue scores) produced
many pre-therapy absolute scores of 0, resulting in a
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 5. A: Overall survival (OS) (solid line) and progression-free survival (PFS) (dashed line) for all patients (n¼ 49) from time of first mIBG
therapy.B: PFS by pre-therapymIBG extension score for low (5, solid line) or high score (>5, dashed line);P¼ 0.20.C: PFS by relative extension
score post-therapy of 0.5 (solid line) or >0.5 (dashed line); P¼ 0.34.
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substantially decreased sample size since these scores were
excluded from the analysis. Ideally, only 10 patients should
have received pre-therapy scores of 0 by Method 2 because
they were documented as having no evidence of soft tissue
disease pre-therapy. However, only two patients received
pre-therapy scores of 0 from all four readers. Even though
these patients’ scans were dropped from the concordance
analysis, failing to assess soft tissue lesions could result in an
inaccurate response evaluation by semi-quantitative score.
Discrepancies in assignment of score for soft tissue lesions
might be eliminated by simply allowing readers to score any
lesion within its appropriate anatomical segment instead of
trying to differentiate between soft tissues or skeletal lesions.
Although the impression of the reader as towhether a scan
was improved, worsened, or stabilized showed reasonable
concordance and correlated with the relative score and the
response by INRC, the accuracy was lower than that of the
semi-quantitative scoring system. For example, only 7/22
(these 7 patients are listed in Table V) patients with a low
relative score of 0.5 had NR or PD, whereas 12/29 (6 of
these 12 are in Table V) patients rated as ‘‘improved’’ on
MIBG scan, fell into the NR or PD category by INRC. This
corresponded to a positive predictive value of 68% for the
relative score versus 59% for the impression. It also resulted
in a false positive fraction of only 20% for the relative score
compared to 34% for the impression.
Despite a strong correlation with response by INRC, the
relative extension scores carried no significance in predicting
PFS. This may be a result of two factors. First, there was no
difference in this group of 49 patients in PFS between those
with response to therapy and those without response.
Secondly, those that were left with residual disease were
also often entered on a new therapy soon after the MIBG
treatment.
The semi-quantitative scoring system must be used in
combination with other response criteria in refractory
neuroblastoma as it only assesses disease visible on mIBG
scan and fails to include analysis of bone marrow andmIBG-
negative disease only evaluable on CT or MR. Current
cooperative high-risk neuroblastoma protocols both in
Europe and in North America are incorporating semi-
quantitative scoring by mIBG scan into their central review
of response, and a recent International Neuroblastoma Risk
Group meeting of cooperative study groups from Asia,
Europe, and North America in September, 2005 reached a
consensus on incorporation of a common scoring system into
their evaluation of response for amore objectivemeasure and
to facilitate comparison between studies. This new system
will assign soft tissue lesionswithin their appropriate skeletal
segment, and divide the body into seven segments: head,
spine, ribs and chest, abdomen and pelvis, arms, legs.
Semi-quantitative scoring of mIBG scans provides amore
reliable method of assessing response in mIBG positive
lesions in patients with relapsed neuroblastoma than a
standard impression reading, especially in patients with
initial scores >3. The scoring system is reproducible with
good intra- and inter-observer concordance and will provide
an important component of overall response criteria for this
disease in patients with recurrent as well as newly diagnosed
neuroblastoma.
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